Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Operating Leases (2024 - 2025)

Historic Operating Leases for Prelude Therapeutics (PRLD) over the last 2 years, with Q3 2025 value amounting to $15.1 million.

  • Prelude Therapeutics' Operating Leases fell 1659.13% to $15.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.1 million, marking a year-over-year decrease of 1659.13%. This contributed to the annual value of $15.3 million for FY2024, which is N/A changed from last year.
  • Latest data reveals that Prelude Therapeutics reported Operating Leases of $15.1 million as of Q3 2025, which was down 1659.13% from $15.2 million recorded in Q2 2025.
  • Prelude Therapeutics' Operating Leases' 5-year high stood at $18.2 million during Q2 2024, with a 5-year trough of $15.1 million in Q3 2025.